Frontotemporal Dementia Management Market
Market Insights onFrontotemporal Dementia Management covering sales outlook, demand forecast & up-to-date key trends
Frontotemporal Dementia Management Market by Drug Class Type, Distribution Channel, End-User & Region | Forecast 2023 to 2033
Frontotemporal Dementia Management Market Snapshot (2023 to 2033)
The global Frontotemporal Dementia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.
According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause of Frontotemporal dementia is still unknown it majorly affects individuals between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 10 Million |
|
Anticipated Forecast Value (2033) |
US$ 17.91 Million |
|
Projected Growth Rate (2023 to 2033) |
6% CAGR |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Frontotemporal Dementia Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Frontotemporal Dementia Management reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Frontotemporal Dementia Management.
The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of dementia patients, increasing research and development investments, and increasing drug development grants and funding by the government, as well as non-government organizations, are propelling immense growth.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Frontotemporal Dementia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dementia and others is fuelling the market growth. Thus, the market for Frontotemporal Dementia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Frontotemporal Dementia Management Market?
Increased Prevalence of the Condition to Push the Market Growth
The high prevalence of dementia is driving the growth of the market owing to treatment advancements and the development of novel therapies for dementia. Furthermore, the vulnerable aging population, government incentives, and benefits through special designation. According to the Centers for Disease Control and Prevention, by 2060, the number of Alzheimer’s disease cases is predicted to rise to an estimated 14 million people, with minority populations being affected the most.
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting drug development as the patient base of Frontotemporal dementia is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia. The population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Frontotemporal Dementia Management Market?
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Frontotemporal Dementia Management, less awareness of the condition, lack of proper diagnosis and higher chances of misunderstanding Alzheimer’s disease, and insubstantial and poor treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Region-Wise Insights
How is the Market for Frontotemporal Dementia Management Market Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling the growth of Frontotemporal Dementia Management in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Frontotemporal Dementia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to the increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
What are the Factors Boosting the Market for Frontotemporal Dementia Management in North America?
Technological Advancements Shaping Landscape for Frontotemporal Dementia Management in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. According to the Centers for Disease Control and Prevention, current estimates are that about 5.8 million people in the USA have Alzheimer’s disease and related dementias, including 5.6 million aged 65 and older and about 200,000 under age 65 with younger-onset Alzheimer’s.
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.A Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Government initiatives, an increase in the number of research partnerships, the presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
By Drug Class Type, Which Segment is Likely to Account for a Prominent Share?
Antidepressants as an effective treatment to drive the market
A study conducted by the National Center for Biotechnology Information included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses related to antidepressant efficacy. To analyze, the organization had nine groups of patients with dementia treated with antidepressants compared with nine groups receiving placebo treatment. As a result, participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks.
Considering this, FMI concludes that there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
By Distribution Channel, Which Segment is Likely to Account for a Significant Share?
Hospital Pharmacies to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during Frontotemporal Dementia Management facilitates the growth of this segment. The majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Start-ups Scenario
Key start-ups in the market include-
- Geras Solutions aims to provide a clear pathway toward a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia-supportive solutions via an easy-to-use mobile health tool.
- Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical needs Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain, and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Market Competition
Key players in the Frontotemporal Dementia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
- In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
- Alzheimer's Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 10 Million |
|
Market Value in 2033 |
US$ 17.91 Million |
|
Growth Rate |
CAGR of 6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey
Drug Class Type:
- Antidepressants
- Fluoxetine
- Fluvoxamine
- Sertraline
- Paroxetine
- Citalopram
- Bupropion
- Mirtazapine
- Antipsychotics
- Olanzapine
- Quetiapine
- Ziprasidone
- Aripiprazole
- Risperidone
- Paliperidone
End-Users:
- Hospitals
- Specialty clinics
- Others
Distribution Channel:
- Hospital Pharmacy
- Drug store
- Retail Pharmacy
- Online Pharmacy
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
From 2018 to 2022, the Frontotemporal Dementia Management Market grew at a CAGR of 4%.
The global Frontotemporal Dementia Management Market is expected to grow with a 6% CAGR during 2023 to 2033.
As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million
According to the FMI analysis, hospital pharmacy account for the largest market share.
North America is expected to possess 25% market share for the Frontotemporal Dementia Management Market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Table of Content
1. Executive Summary | Frontotemporal Dementia Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global analysis 2018 to 2022 and Forecast, 2023 to2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Drug Class Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class Type, 2023 to2033
5.3.1. Antidepressants
5.3.1.1. Fluoxetine
5.3.1.2. Fluvoxamine
5.3.1.3. Sertraline
5.3.1.4. Paroxetine
5.3.1.5. Citalopram
5.3.1.6. Bupropion
5.3.1.7. Mitrazepine
5.3.2. Antipsychotics
5.3.2.1. Olanzapine
5.3.2.2. Quetiapine
5.3.2.3. Ziprasidone
5.3.2.4. Aripiprazole
5.3.2.5. Risperidone
5.3.2.6. Paliperidone
5.4. Y-o-Y Growth Trend Analysis By Drug Class Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class Type, 2023 to2033
6. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to2033
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Drug Store
6.3.4. Online Pharmacy
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to2033
7. Global analysis 2018 to 2022 and Forecast 2023 to2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to2033
8. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America analysis 2018 to 2022 and Forecast 2023 to2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Drug Class Type
9.2.3. By Distribution Channel
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class Type
9.3.3. By Distribution Channel
9.3.4. By End User
9.4. Key Takeaways
10. Latin America analysis 2018 to 2022 and Forecast 2023 to2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class Type
10.2.3. By Distribution Channel
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class Type
10.3.3. By Distribution Channel
10.3.4. By End User
10.4. Key Takeaways
11. Europe analysis 2018 to 2022 and Forecast 2023 to2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class Type
11.2.3. By Distribution Channel
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class Type
11.3.3. By Distribution Channel
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific analysis 2018 to 2022 and Forecast 2023 to2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class Type
12.2.3. By Distribution Channel
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class Type
12.3.3. By Distribution Channel
12.3.4. By End User
12.4. Key Takeaways
13. MEA analysis 2018 to 2022 and Forecast 2023 to2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Class Type
13.2.3. By Distribution Channel
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class Type
13.3.3. By Distribution Channel
13.3.4. By End User
13.4. Key Takeaways
14. Key Country's analysis
14.1. United States of America
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class Type
14.1.2.2. By Distribution Channel
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class Type
14.2.2.2. By Distribution Channel
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class Type
14.3.2.2. By Distribution Channel
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class Type
14.4.2.2. By Distribution Channel
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class Type
14.5.2.2. By Distribution Channel
14.5.2.3. By End User
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class Type
14.6.2.2. By Distribution Channel
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class Type
14.7.2.2. By Distribution Channel
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class Type
14.8.2.2. By Distribution Channel
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class Type
14.9.2.2. By Distribution Channel
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class Type
14.10.2.2. By Distribution Channel
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class Type
14.11.2.2. By Distribution Channel
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class Type
14.12.2.2. By Distribution Channel
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class Type
14.13.2.2. By Distribution Channel
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class Type
14.14.2.2. By Distribution Channel
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class Type
14.15.2.2. By Distribution Channel
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class Type
14.16.2.2. By Distribution Channel
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class Type
14.17.2.2. By Distribution Channel
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class Type
14.18.2.2. By Distribution Channel
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class Type
14.19.2.2. By Distribution Channel
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class Type
14.20.2.2. By Distribution Channel
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class Type
15.3.3. By Distribution Channel
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Novartis AG
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. F. Hoffmann-La Roche Ltd.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. AstraZeneca GmbH
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Sanofi S.A
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Merck & Co., Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. TauRx Pharmaceuticals
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Alector Pharma Co.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Bausch Health Companies Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. GlaxoSmithKline Plc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 19: Asia Pacific Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 20: Asia Pacific Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MEA Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033
Table 23: MEA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 24: MEA Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 2: Global Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 3: Global Value (US$ Million) by End User, 2023 to2033
Figure 4: Global Value (US$ Million) by Region, 2023 to2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to2033
Figure 8: Global Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 10: Global Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 11: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 13: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 14: Global Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 16: Global Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 17: Global attractiveness by Drug Class Type, 2023 to2033
Figure 18: Global attractiveness by Distribution Channel, 2023 to2033
Figure 19: Global attractiveness by End User, 2023 to2033
Figure 20: Global attractiveness by Region, 2023 to2033
Figure 21: North America Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 22: North America Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 23: North America Value (US$ Million) by End User, 2023 to2033
Figure 24: North America Value (US$ Million) by Country, 2023 to2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to2033
Figure 28: North America Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 30: North America Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 31: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 33: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 34: North America Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 36: North America Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 37: North American attractiveness by Drug Class Type, 2023 to2033
Figure 38: North American attractiveness by Distribution Channel, 2023 to2033
Figure 39: North America attractiveness by End User, 2023 to2033
Figure 40: North American attractiveness by Country, 2023 to2033
Figure 41: Latin America Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 42: Latin America Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 43: Latin America Value (US$ Million) by End User, 2023 to2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to2033
Figure 48: Latin America Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 51: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 54: Latin America Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 57: Latin America's attractiveness by Drug Class Type, 2023 to2033
Figure 58: Latin America attractiveness by Distribution Channel, 2023 to2033
Figure 59: Latin America attractiveness by End User, 2023 to2033
Figure 60: Latin America attractiveness by Country, 2023 to2033
Figure 61: Europe Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 62: Europe Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 63: Europe Value (US$ Million) by End User, 2023 to2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to2033
Figure 68: Europe Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 71: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 74: Europe Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 76: Europe Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 77: Europe attractiveness by Drug Class Type, 2023 to2033
Figure 78: Europe attractiveness by Distribution Channel, 2023 to2033
Figure 79: Europe attractiveness by End User, 2023 to2033
Figure 80: Europe attractiveness by Country, 2023 to2033
Figure 81: Asia Pacific Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 82: Asia Pacific Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 83: Asia Pacific Value (US$ Million) by End User, 2023 to2033
Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to2033
Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to2033
Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to2033
Figure 88: Asia Pacific Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 91: Asia Pacific Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 94: Asia Pacific Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Asia Pacific Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 97: Asia Pacific attractiveness by Drug Class Type, 2023 to2033
Figure 98: Asia Pacific attractiveness by Distribution Channel, 2023 to2033
Figure 99: Asia Pacific attractiveness by End User, 2023 to2033
Figure 100: Asia Pacific attractiveness by Country, 2023 to2033
Figure 101: MEA Value (US$ Million) by Drug Class Type, 2023 to2033
Figure 102: MEA Value (US$ Million) by Distribution Channel, 2023 to2033
Figure 103: MEA Value (US$ Million) by End User, 2023 to2033
Figure 104: MEA Value (US$ Million) by Country, 2023 to2033
Figure 105: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MEA Value Share (%) and BPS Analysis by Country, 2023 to2033
Figure 107: MEA Y-o-Y Growth (%) Projections by Country, 2023 to2033
Figure 108: MEA Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033
Figure 109: MEA Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033
Figure 110: MEA Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033
Figure 111: MEA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 112: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033
Figure 113: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033
Figure 114: MEA Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: MEA Value Share (%) and BPS Analysis by End User, 2023 to2033
Figure 116: MEA Y-o-Y Growth (%) Projections by End User, 2023 to2033
Figure 117: MEA attractiveness by Drug Class Type, 2023 to2033
Figure 118: MEA attractiveness by Distribution Channel, 2023 to2033
Figure 119: MEA attractiveness by End User, 2023 to2033
Figure 120: MEA attractiveness by Country, 2023 to2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
